2. Learning Objectives

3. Variable Response to Clopidogrel

4. Platelet Reactivity and Outcomes

5. Clopidogrel Metabolism

6. CYP450 Genetic Variants and PK/PD

7. CYP2C19 and Clinical Outcomes

8. Clopidogrel Boxed Warning

9. CYP2C19 and Treatment With Clopidogrel

10. CURRENT-OASIS 7: Study Design, Flow, and Compliance

11. CURRENT-OASIS 7: Clopidogrel Double (600 mg  150 mg/d x 7d  75 mg/d) vs Standard Dose (300 mg  75 mg/d)

12. CURRENT-OASIS 7: Clopidogrel Double- vs Standard-Dose Bleeding PCI Population

13. Tailoring Clopidogrel Dosing With Platelet Function Monitoring

14. GRAVITAS Study Design

15. GRAVITAS Primary End Point: CV Death, MI, Stent Thrombosis

16. GRAVITAS Pharmacodynamics: Effect of SD vs HD Clopidogrel

17. PRINCIPLE TIMI 44 PRIMARY EP: Acute Phase

18. PRINCIPLE TIMI 44 PRIMARY EP: Maintenance Phase

19. TRITON-TIMI 38 13,608 Patients With ACS and Planned PCI Randomized to Prasugrel (60/10) vs Clopidogrel (300/75)

20. TRITON-TIMI 38 Bleeding Events: Safety Cohort (N = 13,457)

21. TRILOGY-ACS Study Design

22. TRILOGY-ACS: Primary Efficacy End Point to 30 Months (Age < 75 years)

23. Ticagrelor Pharmacodynamics

24. Platelet Reactivity: Ticagrelor vs Prasugrel

25. PLATO Primary Efficacy End Point: CV Death, MI, or Stroke

26. PLATO: Bleeding

27. TRA-CER Primary End Point: CV Death, MI, Stroke, Hospitalization for Ischemia, Urgent Revascularization

28. TRA-CER: Bleeding Outcomes

29. CHAMPION PHOENIX Study Design

30. CHAMPION PHOENIX: Primary Efficacy Outcomes at 48 Hours, MITT

31. CHAMPION PHOENIX: Non-CABG Bleeding at 48 Hours

32. ESC NSTE-ACS Guidelines

33. Periprocedural Antithrombotic Medication in Primary PCI

34. Antiplatelet Therapy in UA/NSTEMI

35. Antiplatelet Therapy to Support Primary PCI for STEMI

36. Case 1

37. Case 2

38. Case 3

39. Conclusions

40. Abbreviations

41. Abbreviations (cont)

42. Abbreviations (cont)

43. Abbreviations (cont)

44. References

45. References (cont)

46. References (cont)

47. References (cont)